- Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE net product sales of $31.0 million, REZLIDHIA net product sales of $7.4 million and GAVRETO net product sales of $8.1 million
- R289 granted Orphan Drug designation by the FDA for the treatment of MDS
- Rigel anticipates 2025 total revenue of approximately $200 to $210 million
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2025.
Comment(0)
Reason For Report